NeuroOne Medical TechnologiesNMTC +3.00%39 PS Ratio is 2.65 as of Jul. 07, 2026, which is 79% below its 10-year median of 12.61. GuruFocus rates NMTC with a GF Score™ of 39/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks better than 53.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NeuroOne Medical Technologies's share price is $3.09.
NeuroOne Medical Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.17. Hence, NeuroOne Medical Technologies's PS Ratio for today is 2.65.
Good Sign:
NeuroOne Medical Technologies Corp stock PS Ratio (=2.65) is close to 10-year low of 2.47.
The historical rank and industry rank for NeuroOne Medical Technologies's PS Ratio or its related term are showing as below:
NMTC'
s PS Ratio Range Over the Past 10 Years
Min: 2.47 Med: 12.61 Max: 1194.55
Current: 2.65
During the past 13 years, NeuroOne Medical Technologies's highest PS Ratio was 1194.55. The lowest was 2.47. And the median was 12.61.
NMTC's PS Ratio is ranked better than 53.91% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs NMTC: 2.65
During the past 13 years, NeuroOne Medical Technologies's highest 3-Year average Revenue per Share Growth Rate was 177.00% per year. The lowest was -40.50% per year. And the median was 0.00% per year.
Back to Basics: PS Ratio
NeuroOne Medical Technologies (NAS:NMTC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NeuroOne Medical Technologies PS Ratio Related Terms
NeuroOne Medical Technologies PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's PS Ratio falls into.
NeuroOne Medical Technologies PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NeuroOne Medical Technologies's Share Price of today is $3.09. NeuroOne Medical Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NeuroOne Medical Technologies (NMTC) has a PS Ratio of 2.65 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NeuroOne Medical Technologies and its competitors. This is 79% below median its historical median of 12.61. Over the past decade, NeuroOne Medical Technologies' PS Ratio has ranged from 2.47 to 1,194.55. According to the industry distribution chart, NeuroOne Medical Technologies ranks #371 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is NeuroOne Medical Technologies' PS Ratio too high?
NeuroOne Medical Technologies' current PS Ratio of 2.65 is 79% below median its 10-year median of 12.61. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 1,194.55. The Medical Devices & Instruments industry median PS Ratio is 2.94. NeuroOne Medical Technologies' value of 2.65 is 9.9% below this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #371 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NeuroOne Medical Technologies has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' PS Ratio compare to RDGL and TANAF?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #371 out of 805 companies for PS Ratio. This puts NeuroOne Medical Technologies in the upper half of its industry. The industry median PS Ratio is 2.94. NeuroOne Medical Technologies' value of 2.65 is 9.9% below this benchmark. Historically, NeuroOne Medical Technologies' own PS Ratio has ranged from 2.47 to 1,194.55 over the past decade. While the company's 10-year median is 12.61 vs. the industry median of 2.94, NeuroOne Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current PS Ratio of 2.65 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current PS Ratio is 2.65, which is 79% below median its own 10-year median of 12.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $3.09 — trading 53.3% below its estimated fair value. The current PS Ratio is 2.65, which is 79% below median its 10-year median of 12.61 and 9.9% below the Medical Devices & Instruments industry median of 2.94. NeuroOne Medical Technologies' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current PS Ratio is 2.65 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued.
The current stock price of $3.09 is trading 53.3% below its estimated GF Value™ of $6.61.
GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.
Key valuation signals for NMTC:
PS Ratio: 2.65 (79% below median its 10-year median of 12.61)
GF Value™: $6.61 vs. price of $3.09 (53.3% below fair value)
Industry Position: 9.9% below the Medical Devices & Instruments median (#371 of 805)
No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroOne Medical Technologies Business Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
39GF Score
Get the complete analysis for NMTC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
